Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 29;12:755866. doi: 10.3389/fimmu.2021.755866

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Que, Xu, Xu, Almeida, Zhu, Wang, Wang, Liu, Jiang, Wang, Li and Zhou

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of clinical response and survival analysis between EMM patients and non-EMM patients receiving anti-BCMA CART cell therapy in two clinical trials conducted in our center (A) ORR was analyzed between EMM and non-EMM. The p value is based on Fisher’s exact test. (B, C) Analysis of PFS and OS for EMM and non-EMM patients using the Kaplan-Meier method. P values less than 0.05 (two-tailed) were considered statistically significant. CR, complete response; EMM, extramedullary myeloma; ORR, objective response rate; MR, minimal response; NR, not reach; OS, overall survival; PD, relapse/progressive disease. PFS, progression-free survival; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.